



Treatments for Obesity Management

Questions for Deliberation and Voting: September 16, 2022 Public Meeting

These questions are intended for the deliberation of the New England CEPAC voting body at the Public Meeting.

Patient Population for all questions: Adults without pre-existing diabetes and either a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).

Clinical Evidence

1. Is the evidence adequate to demonstrate that the net health benefit of **semaglutide** added to lifestyle modification is superior to that provided by **lifestyle modification** alone?

Yes No

2. Is the evidence adequate to demonstrate that the net health benefit of **liraglutide** added to lifestyle modification is superior to that provided by **lifestyle modification** alone?

Yes No

3. Is the evidence adequate to demonstrate that the net health benefit of **phentermine/topiramate** added to lifestyle modification is superior to that provided by **lifestyle modification** alone?

Yes No

4. Is the evidence adequate to demonstrate that the net health benefit of **bupropion/naltrexone** added to lifestyle modification is superior to that provided by **lifestyle modification** alone?

Yes No

5. Is the evidence adequate to demonstrate that the net health benefit of **semaglutide** added to lifestyle modification is superior to that provided by **liraglutide** added to lifestyle modification?

Yes No

6. Is the evidence adequate to demonstrate that the net health benefit of **semaglutide** added to lifestyle modification is superior to that provided by **phentermine/topiramate** added to lifestyle modification?

Yes No

7. Is the evidence adequate to demonstrate that the net health benefit of **semaglutide** added to lifestyle modification is superior to that provided by **bupropion/naltrexone** added to lifestyle modification?

Yes

No

Contextual Considerations and Potential Other Benefits or Disadvantages

Please vote on the following contextual considerations:

When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for obesity on the basis of the following contextual considerations:

1: Very low priority; 2: Low priority; 3: Average priority; 4: High priority; 5: Very high priority

8. Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability
9. Magnitude of the lifetime impact on individual patients of the condition being treated
10. Other (as relevant)

Please vote on the following potential other benefits or disadvantages:

What are the relative effects of semaglutide versus lifestyle modification on the following outcomes that inform judgment of the overall long-term value for money of semaglutide?

1: Major negative effect; 2: Minor negative effect; 3: No difference; 4: Minor positive effect; 5: Major positive effect

11. Patients' ability to achieve major life goals related to education, work, or family life
12. Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life
13. Society's goal of reducing health inequities
14. Other (as relevant)

Long-Term Value for Money

15. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with **semaglutide** added to lifestyle modification versus **lifestyle modification** alone?
 - a. Low long-term value for money at current price
 - b. Intermediate long-term value for money at current price
 - c. High long-term value for money at current price

16. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with **semaglutide** added to lifestyle modification versus **phentermine/topiramate**?
 - a. Low long-term value for money at current price
 - b. Intermediate long-term value for money at current price
 - c. High long-term value for money at current price